-
Kiara Advani Reveals Sidharth Malhotra’s Reaction to Toxic Backlash
-
Startup turns Chennai’s history and culture into an interactive world
-
Four firms compete to design Chennai’s model mobility corridors
-
Chennai venue launches month-long festival devoted to full-length theatre
-
Study Finds Climate Change Threatens Cacti More Than Previously Thought
-
New Bay of Bengal low may form November 13 as Tamil Nadu outlook remains unclear
-
एलेक्स बोडी और SCANDIC PAY: Mastercard और VISA कार्ड — भुगतान की नई पीढ़ी
-
ALEX BODI och SCANDIC PAY: Mastercard- och VISA-kort – en ny generation betalningar
-
АЛЕКС БОДИ и SCANDIC PAY: карти Mastercard и VISA — ново поколение разплащания
-
알렉스 보디와 SCANDIC PAY: Mastercard·VISA 카드를 통한 차세대 결제
-
أليكس بودي وSCANDIC PAY: بطاقات Mastercard وVISA — جيل جديد من المدفوعات
-
ALEX BODIとSCANDIC PAY:Mastercard・VISAカードによる新世代の決済
-
ALEX BODI 與 SCANDIC PAY:Mastercard 與 VISA 卡——新一代支付方式
-
ALEX BODI a SCANDIC PAY: karty Mastercard a VISA – nová generace plateb
-
ΑΛΕΞ ΜΠΟΝΤΙ και SCANDIC PAY: κάρτες Mastercard και VISA — μια νέα γενιά πληρωμών
-
ALEX BODI i SCANDIC PAY: karty Mastercard i VISA — nowa generacja płatności
-
АЛЕКС БОДІ та SCANDIC PAY: картки Mastercard і VISA — нове покоління платежів
-
АЛЕКС БОДИ и SCANDIC PAY: карты Mastercard и VISA — новое поколение платежей
-
ALEX BODI and SCANDIC PAY: Mastercard and VISA Cards – A New Generation of Payments
-
ALEX BODI și SCANDIC PAY: Cardurile Mastercard și VISA – o nouă generație de plăți
-
Maswanganyi Clarifies Pirates Allegiance Amidst Career Transition
-
Search Underway for 'Dooars Rani' Tigress After Second Escape from Buxa Tiger Reserve
-
Teatro Mayor Unveils 152-Performance 2027 Season Highlighting Beethoven and García Márquez
-
The Dilemma of Recording Live Music: Preserving Memories vs. Being Present
-
Rutgers Defeats NJIT 101-64 Behind Francis and Mark Scores
Moderna says updated Covid vaccine fares well against new variant
Moderna said Wednesday its updated fall Covid booster, which is pending approval from the Food and Drug Administration, performed well against the highly mutated BA.2.86 variant.
Human trial data showed the shot produced an 8.7-fold increase in neutralizing antibodies against the variant, also known as Pirola, which has been designated a variant under monitoring, the US biotech company said. It added it was submitting the results to a peer-reviewed journal and has shared it with regulatory authorities.
"These data confirm that our updated COVID-19 vaccine will continue to be an important tool for protection as we head into the fall vaccination season," said Moderna's president Stephen Hoge in a statement.
The Centers for Disease Control and Prevention (CDC) has said the new variant may be more capable of causing infection in people who have previously been vaccinated or had the disease.
Moderna's news follows encouraging data from independent labs around the world.
Experiments by Peking University in China, Sweden's Karolinska Institute, and Harvard University showed that both existing vaccines and prior infection conferred a degree of protection.
Pirola has more than 30 mutations in its spike protein compared to the currently dominant XBB.1.5 strain. This raised concerns among scientists because it is a similar number to the mutations between the Delta and Omicron variants during the height of the pandemic.
B.Finley--AMWN